BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytrenâs contracture and Peyronieâs disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Biospecifics Technologies Corp.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Biospecifics Technologies Corp. market cap is $650.25M.
What is the 52-week high for Biospecifics Technologies Corp.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Biospecifics Technologies Corp. 52 week high is $89.15 as of October 19, 2025.
What is the 52-week low for Biospecifics Technologies Corp.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Biospecifics Technologies Corp. 52 week low is $42.00 as of October 19, 2025.
What was Biospecifics Technologies Corp. stock price yesterday?
Biospecifics Technologies Corp. stock price yesterday was $88.53.
What is the PE ratio of Biospecifics Technologies Corp.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Biospecifics Technologies Corp.’s P/E ratio is 37.55.
What is the Price-to-Book ratio of Biospecifics Technologies Corp.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Biospecifics Technologies Corp. P/B ratio is 4.8054.
What is the 50-day moving average of Biospecifics Technologies Corp.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Biospecifics Technologies Corp. 50-day moving average is $76.94.